YU1497A - Farmaceutska formulacija - Google Patents

Farmaceutska formulacija

Info

Publication number
YU1497A
YU1497A YU1497A YU1497A YU1497A YU 1497 A YU1497 A YU 1497A YU 1497 A YU1497 A YU 1497A YU 1497 A YU1497 A YU 1497A YU 1497 A YU1497 A YU 1497A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical formulation
drug
water
insoluble
core
Prior art date
Application number
YU1497A
Other languages
English (en)
Inventor
E. Leznak Lerner
Moshe Flashuer
Adel Peuhasi
Original Assignee
Perio Products Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perio Products Ltd. filed Critical Perio Products Ltd.
Publication of YU1497A publication Critical patent/YU1497A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmaceutska formulacija koja se sastoji od leka u kombinaciji sa materijalom jezgra, jezgro koje je okruženo materijalom prevlake koja je nerastvorna u vodi ili relativno nerastvorna u vodi, u koju je ugradjen zrnasti materijal nerastvoran u vodi. Kada farmaceutska formulacija dodje u kontakt sa tečnošću koja sadrži vodu zrnasti materijal upija tečnost formirajući pri tome kanale koji povezuju jezgro u kome je sadržan lek sa spoljnom površinom prevlake. Ovi kanali omogućavaju otpuštanje leka iz jezgra u pomenutu tečnost. Kontrolom parametara farmaceutske formulacije lokacija i otpuštanje leka mogu se pažljivo kontrolisati.
YU1497A 1996-01-18 1997-01-17 Farmaceutska formulacija YU1497A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/588,247 US5840332A (en) 1996-01-18 1996-01-18 Gastrointestinal drug delivery system

Publications (1)

Publication Number Publication Date
YU1497A true YU1497A (sh) 1999-09-27

Family

ID=24353076

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1497A YU1497A (sh) 1996-01-18 1997-01-17 Farmaceutska formulacija

Country Status (16)

Country Link
US (1) US5840332A (sh)
EP (1) EP0877604B1 (sh)
JP (1) JP4165905B2 (sh)
CN (1) CN1208343A (sh)
AR (1) AR005451A1 (sh)
AT (1) ATE291417T1 (sh)
AU (1) AU713722B2 (sh)
CZ (1) CZ295932B6 (sh)
DE (1) DE69732830T2 (sh)
ES (1) ES2241031T3 (sh)
IL (1) IL125042A (sh)
MY (1) MY133883A (sh)
NZ (1) NZ324808A (sh)
WO (1) WO1997025979A1 (sh)
YU (1) YU1497A (sh)
ZA (1) ZA97405B (sh)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69528583T2 (de) 1994-04-22 2003-07-10 Yamanouchi Pharmaceutical Co., Ltd. Kolon-spezifisches arzneistofffreisetzungssystem
PL186605B1 (pl) * 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
WO1998005310A1 (fr) * 1996-08-02 1998-02-12 Hisamitsu Pharmaceutical Co., Inc. Gelules destinees a des preparations orales et preparations de gelules destinees a une administration orale
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
DK1021171T3 (da) * 1997-10-09 2003-08-25 Dexcel Pharma Technologies Ltd Lægemiddelfremførelsessystem til forsinket, fuldstændig frigivelse gastrointestinalt
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
ATE269058T1 (de) * 1998-04-22 2004-07-15 Glycologic Ltd Oral anwendbare zubereitungen enthaltend ein kationvernetztes polysaccharid und ein im unteren intestinalen bereich abbaubares polymer
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6328994B1 (en) 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
EP1561458B1 (en) 1998-07-28 2010-09-15 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
US7041313B1 (en) * 1998-08-12 2006-05-09 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
US6514525B2 (en) 1998-09-10 2003-02-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
JP4613275B2 (ja) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6351665B1 (en) 1999-05-07 2002-02-26 Kenneth L Koch Method and apparatus for evaluating myoelectric signals and identifying artifact
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
EP1184038B1 (en) * 1999-06-09 2005-12-28 Mochida Pharmaceutical Co., Ltd. System for release in lower digestive tract
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
PT1183014E (pt) * 1999-06-14 2003-12-31 Cosmo Spa Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US20040258750A1 (en) * 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
ES2288152T3 (es) * 1999-08-09 2008-01-01 Dainippon Sumitomo Pharma Co., Ltd. Preparaciones solidas que contienen polvo de quitosano y procedimiento de produccion asociado.
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20130010512A (ko) 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen
EP1239839A2 (en) 1999-12-23 2002-09-18 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
CN1402632A (zh) * 1999-12-23 2003-03-12 辉瑞产品公司 水凝胶驱动的药物剂型
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
CA2396782A1 (en) * 2000-02-04 2001-08-09 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
IN192159B (sh) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
CN1285333C (zh) * 2000-06-07 2006-11-22 张昊 结肠定位释放的口服制剂及其制备方法
IL137431A0 (en) 2000-07-20 2001-07-24 Slo Flo Ltd A new slow release device for controlled delivery of liquid material
KR100411195B1 (ko) * 2000-09-26 2003-12-18 한국화학연구원 케토롤락 트로메타민이 함유된 서방형 펠렛
KR100960200B1 (ko) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6932861B2 (en) * 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
WO2002043694A2 (en) 2000-11-28 2002-06-06 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
WO2002094173A2 (en) * 2001-05-22 2002-11-28 Euro-Celtique Tamper resistant oral dosage form
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
US7550156B2 (en) 2001-11-23 2009-06-23 Rohm And Haas Company Optimised pellet formulations
BR0215262A (pt) * 2001-12-20 2004-12-28 Pharmacia Corp Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
DE50210696D1 (de) * 2002-01-15 2007-09-27 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Orale Vakzinierung mit nackten Tumor-Antigen-Mimotopen
WO2003059380A2 (de) * 2002-01-15 2003-07-24 Bio Life Science Forschungs Und Entwicklungsges M.B.H. Orale vakzinierung
US20040071780A1 (en) * 2002-01-16 2004-04-15 Lillard James W. PACE-A microspheres for delivery of antigens
EA200401145A1 (ru) * 2002-03-05 2005-08-25 Рэнбакси Лабораториз Лимитед Оральная фармацевтическая композиция с модифицированным высвобождением
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
US6986901B2 (en) 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
FR2843872B1 (fr) 2002-08-29 2005-08-19 C T M Ct De Transfert Des Micr Dispositif de localisation equipant une capsule intestinale
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
CN1322865C (zh) * 2002-11-14 2007-06-27 北京东方凯恩医药科技有限公司 用于治疗菌痢的口服结肠定位给药组合物
US9561182B2 (en) 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US20040096497A1 (en) * 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1670442A4 (en) * 2003-09-19 2011-09-14 Penwest Pharmaceuticals Co DOSAGE FORMS WITH DELAYED RELEASE
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1718148A2 (en) * 2004-02-03 2006-11-08 The Regents of the University of California Methods of treating irritable bowel syndrome
AU2005247195A1 (en) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
EP1814541A4 (en) * 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd STABLE ATORVASTATIN FORMULATIONS
US20090196889A1 (en) * 2004-11-22 2009-08-06 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
FR2878159B1 (fr) * 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US8147805B2 (en) * 2005-01-05 2012-04-03 The Board of Regents of The University of T exas System Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CN101146521A (zh) * 2005-03-14 2008-03-19 太阳医药高级研究有限公司 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
EP1863449A2 (en) * 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
MX2007012763A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de liberacion controlada que comprenden una cefalosporina para el tratamiento de infeccion bacteriana.
SI2444079T1 (sl) 2005-05-17 2017-05-31 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje očesnih motenj
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20070082027A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Jr Compositions and methods for reducing food intake and controlling weight
US20070082029A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Fiber satiety compositions
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2008003043A2 (en) 2006-06-28 2008-01-03 Surmodics, Inc. Combination degradable and non-degradable matrices for active agent delivery
SI2049123T1 (sl) 2006-08-03 2013-04-30 Horizon Pharma Ag Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida
US8889184B2 (en) * 2006-09-07 2014-11-18 Losan Pharma Gmbh Particulate form of a pharmaceutical composition which is easy to swallow
EP2079448A2 (en) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
JP2010510196A (ja) * 2006-11-17 2010-04-02 ダ・ボルテラ オイドラギット被覆を施した亜鉛／ペクチンビーズを使用する結腸送達
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
EP2209371B1 (en) 2007-10-19 2017-01-04 SARcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
ES2729925T3 (es) 2007-11-13 2019-11-07 Meritage Pharma Inc Composiciones de corticosteroides
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2425762T3 (es) * 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US8945615B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
JP2012520268A (ja) * 2009-03-13 2012-09-06 ダ・ボルテラ グラム陰性細菌の除去のための組成物及び方法
EP2440210A4 (en) * 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
US8568776B2 (en) 2011-02-11 2013-10-29 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
SG10201606751XA (en) * 2011-05-13 2016-10-28 Eb Ip Hybritabs B V Drug Delivery System
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US10154964B2 (en) * 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9085553B2 (en) 2012-07-25 2015-07-21 SARcode Bioscience, Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
WO2014152754A2 (en) 2013-03-15 2014-09-25 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
MD20150089A2 (ro) * 2013-03-26 2016-03-31 Lipid Therapeutics Gmbh Formă preparativă farmaceutică conţinând fosfatidilcolină pentru tratarea colitei ulceroase
RU2647462C2 (ru) 2013-04-23 2018-03-15 ЗедЭкс ФАРМА, ЭлЭлСи Композиция, состоящая из множества частиц, покрытых кишечнорастворимой оболочкой и имеющих белковую внутреннюю оболочку
WO2015173697A1 (en) 2014-05-12 2015-11-19 Alfa Wassermann S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
EP3725357A1 (en) 2014-06-11 2020-10-21 Massachusetts Institute Of Technology Residence structures and related methods
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
US9956292B2 (en) 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
WO2016178971A1 (en) 2015-05-01 2016-11-10 Massachusetts Institute Of Technology Triggerable shape memory induction devices
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
KR20180090881A (ko) 2015-12-08 2018-08-13 린드라 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
JP7132128B2 (ja) * 2016-04-25 2022-09-06 ジェレシス，エルエルシー 便秘の治療方法
KR20190008265A (ko) 2016-05-06 2019-01-23 피지션즈 씰, 엘엘씨 발레리안 조성물 및 관련 방법
AU2017268840B2 (en) 2016-05-27 2022-02-10 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
JP6780412B2 (ja) * 2016-09-28 2020-11-04 ライオン株式会社 コーティング組成物ならびにコーティング製剤及びその製造方法
AU2017336154B2 (en) 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
US10940113B2 (en) * 2017-02-24 2021-03-09 Medical And Pharmaceutical Industry Technology And Development Center Pharmaceutical composition for colon targeting, method for treating a colon-related disease using the same and preparation method thereof
WO2018227147A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US20210138097A1 (en) * 2018-05-08 2021-05-13 Jonathan M. Protz Methods and compositions for drug targeted delivery
US11839666B2 (en) 2020-10-19 2023-12-12 The Procter & Gamble Company Oral care article comprising a hydrophobic delivery carrier and solid hydrophilic particles comprising an agent
CN114224860B (zh) * 2021-11-06 2023-04-28 山东润德生物科技有限公司 氨基葡萄糖钙片制剂及其制备方法与应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
SE7504049L (sv) * 1975-04-09 1976-10-10 Haessle Ab Colonpreparation
DE2717707C3 (de) * 1977-04-21 1979-11-22 Chephasaar Chemisch-Pharmazeutische Fabrik Gmbh, 6670 St Ingbert Karamellisierte Lactulose
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS57197214A (en) * 1981-05-29 1982-12-03 Tanabe Seiyaku Co Ltd Rapid-releasing microcapsule and its preparation
JPS5858145A (ja) * 1981-10-05 1983-04-06 Tanabe Seiyaku Co Ltd 速放性マイクロカプセル
JPS5867616A (ja) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd 腸溶性マイクロカプセル
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4668517A (en) * 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DE3769707D1 (de) * 1986-06-17 1991-06-06 Recordati Chem Pharm Therapeutisches system mit geregelter wirkstoffabgabe.
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
DK110188D0 (da) * 1988-03-02 1988-03-02 Claus Selch Larsen High molecular weight prodrug derivatives of antiinflammatory drugs
US4857331A (en) * 1988-03-31 1989-08-15 Warner-Lambert Company Sugarless pectin delivery system
IT1219942B (it) * 1988-05-13 1990-05-24 Fidia Farmaceutici Esteri polisaccaridici
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
DE4006521A1 (de) * 1990-03-02 1991-09-05 Bayer Ag Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
DE9015551U1 (de) * 1990-11-14 1992-03-12 Röhm GmbH, 6100 Darmstadt Orale Arzneiform und Überzugsmittel, enthaltend ein im Colon abbaubares Polysaccarid
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
NZ286242A (en) * 1991-03-26 1997-11-24 Csl Ltd Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE4236025A1 (de) * 1992-10-24 1994-04-28 Merck Patent Gmbh Orale Arzneiformen
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
DE4318375A1 (de) * 1993-05-28 1994-12-01 Rottendorf Pharma Gmbh Mischung zur Schaffung von Filmüberzügen für Tabletten od. dgl.
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif

Also Published As

Publication number Publication date
ES2241031T3 (es) 2005-10-16
AU713722B2 (en) 1999-12-09
EP0877604B1 (en) 2005-03-23
NZ324808A (en) 1999-10-28
CN1208343A (zh) 1999-02-17
ZA97405B (en) 1997-07-30
EP0877604A1 (en) 1998-11-18
DE69732830D1 (de) 2005-04-28
CZ219898A3 (cs) 1998-12-16
ATE291417T1 (de) 2005-04-15
AU1206597A (en) 1997-08-11
DE69732830T2 (de) 2006-04-13
MY133883A (en) 2007-11-30
JP4165905B2 (ja) 2008-10-15
IL125042A0 (en) 1999-01-26
IL125042A (en) 2005-03-20
CZ295932B6 (cs) 2005-12-14
JP2000503316A (ja) 2000-03-21
WO1997025979A1 (en) 1997-07-24
AR005451A1 (es) 1999-06-23
US5840332A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
YU1497A (sh) Farmaceutska formulacija
CA2383220A1 (en) Controlled release pellet formulation
ATE331024T1 (de) Wasserlösliche packung enthaltend eine flüssige zusammensetzung mit einer visuell unterscheidbaren kapsel oder emulsion oder dispersionsschicht
KR930700083A (ko) 액상 약물 전달용 삼투 투약 시스템
DE69917618D1 (de) Zusammensetzung mit kontrollierter wirkstoff-freisetzung
ATE33097T1 (de) Zusammensetzung zum ueberziehen von nahrungsund arzneimitteln und derart ueberzogene granulate.
ATE267007T1 (de) Pharmazeutische tablette geeignet zur wirkstofffreisetzung in aufeinanderfolgenden und vorherbestimmbaren zeiträumen
KR900007397A (ko) 서방성 제제
ES2018468B3 (es) Sistema para la liberacion de sustancias activas a velocidad controlada.
DE3578123D1 (de) Arzneipraeparate mit geregelter wirkstoffabgabe.
WO2012009144A3 (en) A bioactive dose containing a material for modulating ph of a bodily fluid
AR010198A1 (es) Microcapsula que comprende material inmiscible en agua salada dentro de una pared de recubrimiento de un policondensado, procedimiento para su preparacion, metodo para controlar una plaga y composicion plaguicida
BRPI9915142B8 (pt) novo material farmacêutico no formato de pérolas com liberação controlada, respectivo método de produção e formulação de múltiplas inidades compreendendo o mesmo
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
JPS56140915A (en) Pharmaceutical preparation for solid drug
DE59806578D1 (de) Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten zum Überziehen von pharmazeutischen oder agrochemischen Darreichungsformen
DE60323474D1 (de) Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
RS49703B (sr) Farmaceutske kompozicije koje sadrže vitamin d i kalcijum, njihovo dobijanje i upotreba
AR009696A2 (es) Dispositivo inhalador para administrar un polvo seco medicamentoso, procedimiento para su realizacion y envase de burbujas para ser usado con dicho dispositivo.
RS50341B (sr) Veterinarska formulacija za davanje vodo-nerastvornih lekova željenoj životinji kroz sistem za distribuciju vode
EP0040472A3 (en) Spray dried n-acetyl-p-aminophenol compositions and method for manufacture thereof
FI822441L (fi) Pao xantinderivat baserade, magen icke irriterande laekemedelsprodukter och foerfarande foer deras framstaellning
KR900004328A (ko) 약체 약제 제형용 제어 방출 치료 시스템
WO2003075894A8 (en) A system for the controlled release of active ingredients
CA2227740A1 (en) Gastrointestinal drug composition